Where Will AST SpaceMobile Be In 5 Years?
Ever tried to send a text from the Nevada desert…
Buy
60
LLY Quote, Financials, Valuation and Earnings
Last price:
$820.22
Seasonality move
:
0.08%
Day range:
$808.10 - $825.00
52-week range:
$677.09 - $972.53
Dividend yield:
0.68%
P/E ratio:
66.67x
P/S ratio:
15.10x
P/B ratio:
46.66x
Volume:
2.8M
Avg. volume:
4.2M
1-year change:
-7.24%
Market cap:
$735.6B
Revenue:
$45B
EPS (TTM):
$12.29
Analysts' Opinion
-
Consensus RatingEli Lilly and has received a consensus rating of Buy. The company's average rating is a Buy based on 16 Buy ratings, 4 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $951.98, Eli Lilly and has an estimated upside of 16.19% from its current price of $819.36.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $650.00 representing 20.67% downside risk from its current price of $819.36.
Fair Value
-
According to the consensus of 21 analysts, Eli Lilly and has 16.19% upside to fair value with a price target of $951.98 per share.
LLY vs. S&P 500
-
Over the past 5 trading days, Eli Lilly and has overperformed the S&P 500 by 6.84% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Eli Lilly and does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Eli Lilly and has grown year-over-year revenues for 8 quarters straight. In the most recent quarter Eli Lilly and reported revenues of $12.7B.
Earnings Growth
-
Eli Lilly and has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Eli Lilly and reported earnings per share of $3.06.
Enterprise value:
770.9B
EV / Invested capital:
14.18x
Price / LTM sales:
15.10x
EV / EBIT:
53.37x
EV / Revenue:
15.73x
PEG ratio (5yr expected):
0.82x
EV / Free cash flow:
-607.14x
Price / Operating cash flow:
1,732.74x
Enterprise value / EBITDA:
47.37x
Gross Profit (TTM):
$40B
Return On Assets:
14.63%
Net Income Margin (TTM):
22.67%
Return On Equity:
78.25%
Return On Invested Capital:
24.21%
Operating Margin:
42.49%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $27.7B | $35.9B | $49B | $8.8B | $12.7B | |
| Gross Profit | $21.5B | $28.8B | $40B | $7.1B | $10.5B | |
| Operating Income | $7.7B | $11.8B | $20.2B | $2.7B | $5.4B | |
| EBITDA | $8.1B | $9.7B | $16.3B | $3.1B | $4.2B | |
| Diluted EPS | $6.19 | $6.79 | $12.29 | $2.48 | $3.06 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $16.6B | $17B | $20.8B | $25.2B | $41.3B | |
| Total Assets | $46.8B | $46.9B | $53.2B | $63.9B | $89.4B | |
| Current Liabilities | $11.7B | $13.4B | $16B | $18.6B | $30.1B | |
| Total Liabilities | $39.7B | $37.5B | $41.9B | $51B | $73.5B | |
| Total Equity | $7.1B | $9.5B | $11.3B | $12.9B | $15.8B | |
| Total Debt | $16.2B | $16.5B | $18.9B | $26.2B | $38.5B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $6.8B | $3.7B | $9.3B | $1.2B | $1.7B | |
| Cash From Investing | -$3.4B | -$7.6B | -$11.5B | -$1.2B | -$3.4B | |
| Cash From Financing | -$2.1B | $2.8B | $2.9B | -$311.3M | $1.4B | |
| Free Cash Flow | $3.8B | -$3.9B | -$1.3B | $83.2M | -$1.6B | |
LLY
Sector
Market Cap
$735.6B
$32.3M
Price % of 52-Week High
84.25%
46.89%
Dividend Yield
0.68%
0%
Shareholder Yield
0.79%
-0.66%
1-Year Price Total Return
-7.24%
-37.62%
Beta (5-Year)
0.404
0.632
Dividend yield:
0.68%
Annualized payout:
$5.20
Payout ratio:
43.74%
Growth streak:
10 years
Technicals
8-day SMA
Buy
Level
$790.29
200-day SMA
Sell
Level
$828.05
Bollinger Bands (100)
Buy
Level
749.33 - 867.13
Chaikin Money Flow
Buy
Level
1.2B
20-day SMA
Buy
Level
$756.92
Relative Strength Index (RSI14)
Buy
Level
64.93
ADX Line
Buy
Level
22.13
Williams %R
Sell
Level
-5.0962
50-day SMA
Buy
Level
$774.35
MACD (12, 26)
Buy
Level
9.45
25-day Aroon Oscillator
Buy
Level
56
On Balance Volume
Neutral
Level
1.4B
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (7.8952)
Sell
CA Score
(Annual)
Level (-0.8597)
Sell
Beneish M-Score
(Annual)
Level (-2.1756)
Buy
Momentum Score
Level (8)
Buy
Ohlson Score
Level (-0.2307)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (10)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Stock Forecast FAQ
In the current month, LLY has received 16 Buy ratings 4 Hold ratings, and 1 Sell ratings. The LLY average analyst price target in the past 3 months is $951.98.
-
Where Will Eli Lilly and Stock Be In 1 Year?
According to analysts, the consensus estimate is that Eli Lilly and share price will rise to $951.98 per share over the next 12 months.
-
What Do Analysts Say About Eli Lilly and?
Analysts are divided on their view about Eli Lilly and share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Eli Lilly and is a Sell and believe this share price will drop from its current level to $650.00.
-
What Is Eli Lilly and's Price Target?
The price target for Eli Lilly and over the next 1-year time period is forecast to be $951.98 according to 21 Wall Street analysts, 16 of them rate the stock a Buy, 1 rates the stock a Sell, and 4 analysts rate the stock a Hold.
-
Is LLY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Eli Lilly and is a Buy. 16 of 21 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of LLY?
You can purchase shares of Eli Lilly and via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Eli Lilly and shares.
-
What Is The Eli Lilly and Share Price Today?
Eli Lilly and was last trading at $820.22 per share. This represents the most recent stock quote for Eli Lilly and. Yesterday, Eli Lilly and closed at $819.36 per share.
-
How To Buy Eli Lilly and Stock Online?
In order to purchase Eli Lilly and stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is TTD The Big Winner If Pharma Ads Are Banned?
Last week, Senators Bernie Sanders and Angus King introduced a…
Is Palantir Stock Overvalued?
By every traditional yardstick, including a price‑to‑sales well above 100,…
Stock Ideas
Buy
65
Is MSFT Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 40x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 48x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Alerts
Sell
11
VEON alert for Jun 16
VEON [VEON] is up 3.15% over the past day.
Buy
74
DAVE alert for Jun 16
Dave [DAVE] is up 3.49% over the past day.
Buy
54
DAR alert for Jun 16
Darling Ingredients [DAR] is up 8.25% over the past day.
